Matthew L. Posard - May 5, 2023 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
Director
Signature
/s/ James Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
May 5, 2023
Transactions value $
$0
Form type
4
Date filed
5/9/2023, 06:27 PM
Previous filing
Dec 6, 2022
Next filing
Jun 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Award $0 +8.07K +7.67% $0.00 113K May 5, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Award $0 +11.4K $0.00 11.4K May 5, 2023 Common Stock 11.4K $31.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
F2 Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.